SynthesisAesthetic plastic surgery2026
Hyaluronidase Protocol in Management of Hyaluronic Acid Filler-Related Vascular Complications: A Systematic Review and Meta-Analysis.
Synthesis in Aesthetic plastic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The Safety Profile of a Portfolio of Hyaluronic Acid-Based Soft Tissue Fillers Manufactured Using MACRO Technology: A Systematic Review of Clinical Evidence.Life (Basel, Switzerland) · 2026Review
- Staged Management of Vascular Occlusion With Ellansé (Polycaprolactone): A Modified Delphi Expert Consensus.Aesthetic surgery journal. Open forum · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHyaluronic acid (HA) fillers are widely used in aesthetic procedures but can lead to serious vascular complications, including skin necrosis and visual impairment. The timely administration of hyaluronidase (HYAL) is critical for mitigating these adverse effects. This systematic review and meta-analysis aim to evaluate the efficacy and propose a management protocol of HYAL in managing HA-related vascular complications.
methodsA comprehensive literature search was conducted across MEDLINE, PubMed, Cochrane, and Web of Science for studies published from 2000 to February 2025. Eligible studies included randomized controlled trials, cohort studies, and case series involving HYAL treatment for HA-related complications. Data extraction focused on treatment protocols, patient demographics, outcomes, and resolution rates.
resultsTwenty-one studies involving 231 patients were included. The mean age was 30.1 years, with a predominance of female patients (90.9%). Skin necrosis occurred in 60.6% of cases and visual impairment in 52.8%. The overall resolution rates for skin necrosis and visual impairment were 78.4% and 45.2%, respectively. Early intervention (within 6 hours) significantly improved outcomes, with higher doses of HYAL correlating with better resolution rates in skin necrosis.
conclusionThis study underscores the effectiveness of hyaluronidase in treating HA-related vascular complications, particularly when administered promptly. The findings support the establishment of standardized treatment protocols to enhance patient safety and outcomes in aesthetic practices. Future research should focus on optimizing dosing strategies and further elucidating the role of adjunctive therapies. LEVEL OF EVIDENCE IV: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
Indexed as
Identifiers
41249530What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.